Thus, despite current anti-VEGF treatment had good clinical results on ROP, new therapeutic target is strongly required to avoid potential adverse effect by targeting VEGF directly for the treatment of ROP [6]. This evidence concerns the gene VEGFA and retinopathy of prematurity.